8-K: Avanos Medical Appoints David Pacitti as New CEO, Effective April 14, 2025

Avanos Medical names David Pacitti as its new Chief Executive Officer, bringing extensive healthcare industry experience to the role.

Summary

• Avanos Medical, Inc. announced the appointment of David Pacitti as the new CEO, effective April 14, 2025.
• Mr. Pacitti joins Avanos from Siemens Healthineers, where he served as President and Head of the Americas.
• His compensation includes a base salary of $1,050,000 per year and eligibility for an annual cash incentive program with a bonus target of 110% of his base salary.
• He is also eligible for annual long-term incentive grants with a target award value for 2026 of $5,000,000.
• Mr. Pacitti will receive a one-time equity award of performance-based restricted share units (PRSUs) with an award value equal to $3,500,000, vesting on the third anniversary of the grant date based on stock price targets.
• He will also receive a one-time equity award of time-based restricted share units (TRSUs) with an award value equal to $3,500,000, vesting over three years.
• Additionally, Mr. Pacitti will receive a one-time $500,000 cash payment within 30 days of his start date.
• He will participate in standard employee benefit plans and the Companys Executive Severance Plan, Severance Pay Plan, and Executive Level Relocation Program.

Sentiment

Score: 7

Explanation: The announcement is generally positive, highlighting the appointment of a new CEO with a strong background and a compensation package designed to incentivize performance. The sentiment is moderately positive as it signals a new chapter for the company.

Positives

• Avanos has secured an experienced leader in David Pacitti, who has a strong background in the healthcare sector.
• Mr. Pacitti's compensation package includes significant incentives tied to the company's performance, aligning his interests with those of the shareholders.
• The performance-based restricted share units (PRSUs) provide a strong incentive for Mr. Pacitti to drive share price appreciation.

Risks

• The vesting of the performance-based restricted share units (PRSUs) is contingent on Avanos' stock price reaching specific targets, which may not be achieved.
• If Mr. Pacitti voluntarily leaves Avanos before the one-year anniversary of his start date, he will be obligated to repay the $500,000 cash award.
• If Mr. Pacitti voluntarily leaves the organization before the second anniversary of his start date, he will be obligated to repay to Avanos any relocation payments he has received under the Relocation Program.

Future Outlook

Avanos expects that David Pacitti's leadership will drive the company's next phase of growth and success, building on its strong portfolio of market-leading products and commitment to delivering breakthrough medical device solutions.

Management Comments

• Gary Blackford, chair of the Avanos board of directors, stated that David Pacitti's extensive industry expertise, leadership acumen, and strategic vision make him the ideal choice to lead Avanos.
• David Pacitti stated that he is honored to lead such a dynamic organization and looks forward to building on Avanos' success and driving long-term value for its stakeholders.

Industry Context

The appointment of David Pacitti, a seasoned executive from Siemens Healthineers, reflects a trend in the medical technology industry of bringing in experienced leaders to drive growth and innovation. His background in medical imaging, laboratory diagnostics, and therapy solutions aligns with Avanos' focus on delivering clinically superior medical device solutions.

Comparison to Industry Standards

• Executive compensation packages in the medical technology industry often include a mix of base salary, short-term incentives (bonuses), and long-term incentives (equity awards).
• The base salary of $1,050,000 is competitive with CEO compensation at similarly sized medical device companies.
• The performance-based restricted share units (PRSUs) are a common tool used to align executive compensation with shareholder value creation, similar to practices at companies like Medtronic and Boston Scientific.
• The stock price targets for PRSU vesting ($20.00, $25.00, $29.00, and $33.00) suggest a focus on driving significant share price appreciation over the three-year performance period.

Management Changes

Stakeholder Impact

• Shareholders are likely to view the appointment of an experienced CEO positively, potentially leading to increased confidence in the company's future prospects.
• Employees may experience changes in leadership style and strategic direction under the new CEO.
• Customers and suppliers may see changes in the company's product offerings and business relationships over time.

Next Steps

• David Pacitti will assume the role of CEO on April 14, 2025.
• The Compensation Committee will determine the mix of long-term incentive vehicles and their overall design for 2026.
• Mr. Pacitti will need to provide the Company with his SEC filing codes to file Section 16 reports.

Key Dates